We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sygnature Chemical Services Announces Significant Increase in Medicinal Chemistry Team
News

Sygnature Chemical Services Announces Significant Increase in Medicinal Chemistry Team

Sygnature Chemical Services Announces Significant Increase in Medicinal Chemistry Team
News

Sygnature Chemical Services Announces Significant Increase in Medicinal Chemistry Team

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sygnature Chemical Services Announces Significant Increase in Medicinal Chemistry Team"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sygnature Chemical Services Ltd., gave an up-date on its recruitment activities. Due to an unprecedented demand for its services from clients in the USA and Europe, over the preceding six months Sygnature has recruited a further 15 experienced medicinal chemists, including significant numbers from AstraZeneca R&D Charnwood in Loughborough and Merck in Newhouse. Sygnature now employs 40 medicinal chemists in its modern, purpose-built facility in BioCity Nottingham.

Commenting on the success of the recent recruitment drive, Dr Simon Hirst, Sygnature’s CEO said, “We are delighted to have been able to attract a substantial number of graduate and PhD qualified medicinal chemists with between 8 - 22 years drug discovery experience in major pharmaceutical companies. AstraZeneca's research facility, located nearby in Loughborough, specializes in R&D for inflammatory respiratory diseases and is a major employer in the East Midlands region. The Merck site in Newhouse, Scotland, specialized in CNS disease R&D.

The expertise brought by the new chemists complements what we already had in-house and further strengthens our drug discovery know-how and expertise in asthma, chronic obstructive pulmonary disease, neurodegeneration, psychiatry and pain. I am confident that the addition to these experienced chemists will help fuel our continued growth through 2011 and beyond,” said Hirst.

Dr Prem Meghani who also recently joined Sygnature as a Scientific Group Leader from AstraZeneca commented, “I am pleased to be working at Sygnature with some of my former AZ colleagues. Sygnature is a dynamic working environment and it is great to be applying our combined drug discovery experience to clients’ discovery programmes. Sygnature is fast becoming a major player in medicinal chemistry-driven drug discovery. The addition of more scientists with big pharma experience to the Sygnature team broadens and expands our in-house drug discovery capability.”

Advertisement